Abstract
Objective: To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma. Methods: 60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly, with 30 cases in each group. Bortezomib combined with dexamethasone was administered in the control group, and bortezomib combined with dexamethasone and lenalidomide was given to the observation group, and the treatment effect was analyzed. Results: After treatment, CD3+ and CD4+ of the observation group were higher than that of the control group, CD8+ was lower than that of the control group, and the total treatment efficiency was higher, which was statistically significant (P < 0.05), and there was no difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe, thus it can be promoted in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
